Quidel Corporation  

(Public, NASDAQ:QDEL)   Watch this stock  
Find more results for QDEL
24.17
+0.02 (0.08%)
Apr 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.47 - 24.47
52 week 15.15 - 26.98
Open 24.23
Vol / Avg. 236,856.00/183,337.00
Mkt cap 803.25M
P/E 235.58
Div/yield     -
EPS 0.10
Shares 33.21M
Beta 1.22
Inst. own 93%
Jul 25, 2017
Q2 2017 Quidel Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 17, 2017
Quidel Corp Annual Shareholders Meeting (Estimated) - 11:30AM EDT - Add to calendar
Apr 24, 2017
Q1 2017 Quidel Corp Earnings Call
Apr 24, 2017
Q1 2017 Quidel Corp Earnings Release
Mar 15, 2017
Quidel Corp at Barclays Global Healthcare Conference - Webcast
Feb 8, 2017
Q4 2016 Quidel Corp Earnings Call - Webcast
Feb 8, 2017
Q4 2016 Quidel Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 19.39% -7.21%
Operating margin 26.09% -2.32%
EBITD margin - 9.64%
Return on average assets 14.46% -3.47%
Return on average equity 27.25% -6.59%
Employees 627 -
CDP Score - -

Address

12544 High Bluff Dr Ste 200
SAN DIEGO, CA 92130-3050
United States - Map
+1-858-5521100 (Phone)
+1-858-4534338 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women's health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Officers and directors

Kenneth F. Buechler Ph.D. Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Douglas C. Bryant President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Randall J. Steward Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Robert Joseph Bujarski J.D. Senior Vice President - Business Development, General Counsel and Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Michael D. Abney Jr. Senior Vice President - Distribution
Age: 52
Bio & Compensation  - Reuters
Werner Kroll Ph.D Senior Vice President,R&D
Age: 59
Bio & Compensation  - Reuters
Edward Keith Russell Senior Vice President - Global Commercial Operations
Age: 48
Bio & Compensation  - Reuters
John D. Tamerius Ph.D. Senior Vice President - Strategic and External Affairs
Age: 70
Bio & Compensation  - Reuters
Charles P. Slacik CPA Director
Age: 61
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 69
Bio & Compensation  - Reuters